Investigational drug · Phase 3
JNJ-101556143
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostatic Neoplasms.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "JNJ-101556143"
First trial start
2026
Sep 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-101556143", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostatic Neoplasms
Approved drugs for the same conditions: Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-101556143" as an intervention, largest first.
- A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07906717 · 400 participants (planned) · Start Oct 29, 2026 · Primary completion Feb 14, 2028
Drug: JNJ-101556143; Placebo and 1 more · For: Prostatic Neoplasms
Sites: El Paso, Texas; The Woodlands, Texas; Murray, Utah · 4 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06095089 · 355 participants (planned) · Start Nov 1, 2023 · Primary completion Jun 21, 2027
Drug: JNJ-78278343; JNJ-87189401 and 3 more · For: Prostatic Neoplasms
Sites: Aurora, Colorado; Atlanta, Georgia; Minneapolis, Minnesota · 22 sites in all
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05818683 · 300 participants (planned) · Start Apr 26, 2023 · Primary completion Aug 31, 2027
Drug: Pasritamig; Cetrelimab and 8 more · For: Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer
Sites: Sarasota, Florida; Grand Rapids, Michigan; Brooklyn, Mississippi · 15 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06800313 · 190 participants (planned) · Start Feb 6, 2025 · Primary completion Aug 17, 2028
Drug: JNJ-101556143 Formulation 1; JNJ-101556143 Formulation 2 and 1 more · For: Metastatic Prostate Cancer
Sites: Colorado Springs, Colorado; Denver, Colorado; New Haven, Connecticut · 18 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07832292 · 100 participants (planned) · Start Sep 16, 2026 · Primary completion May 17, 2029
Drug: JNJ-101556143 · For: Prostatic Neoplasms
Sites: Largo, Florida; Chicago Ridge, Illinois; Carmel, Indiana · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostatic Neoplasms
- OpevesostatMK-5684, ODM-208Phase 37 trials
Merck & Co. · Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials
Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- ARDTPhase 32 trials
Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- QLH12016Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Prostatic Neoplasms, Advanced Prostate Cancer
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.